Clinical Trial Update: Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia [Phase 2]

View source ↗

Summary

Phase 2 trial update on efficacy and safety of allogeneic dendritic cell therapy DCP-001 in Acute Myeloid Leukemia in remission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• DCP-001

Snippet

Sponsor: Mendus | Conditions: Acute Myeloid Leukemia in Remission | Phase 2 | Status: UNKNOWN